US2006040885A1PendingUtilityA1

Bioprosthetic heart valves

54
Assignee: MAYO FOUNDATIONPriority: Sep 21, 1999Filed: Aug 19, 2005Published: Feb 23, 2006
Est. expirySep 21, 2019(expired)· nominal 20-yr term from priority
Inventors:Nalini M. Rajamannan
C12N 2710/10343A61L 27/507C12N 2501/70A61L 27/3695C12N 2510/00C12N 5/0602C12N 2501/03A61K 31/7052A61L 27/38G01N 33/5088G01N 33/5008C12Y 114/13039A61L 27/3645A61K 38/44C12N 15/86A61K 31/40A61K 48/0075A61K 31/5377A61L 27/3625A61K 31/366A61K 31/22A61K 48/005A61K 31/404G01N 33/5061G01N 33/5064A61L 27/3683G01N 33/5011
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

Claims

exact text as granted — not AI-modified
1 - 29 . (canceled)  
   
   
       30 . A method for treating carcinoid heart disease in a mammal, said method comprising administering a serotonin receptor antagonist to said mammal.  
   
   
       31 . The method of  claim 30 , wherein said antagonist is specific for a 5HT1B receptor.  
   
   
       32 . The method of  claim 30 , wherein said antagonist comprises a β-blocker.  
   
   
       33 . The method of  claim 30 , wherein said antagonist is pindolol.  
   
   
       34 - 35 . (canceled)

Join the waitlist — get patent alerts

Track US2006040885A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.